JP2021518344A5 - - Google Patents
Info
- Publication number
- JP2021518344A5 JP2021518344A5 JP2020548995A JP2020548995A JP2021518344A5 JP 2021518344 A5 JP2021518344 A5 JP 2021518344A5 JP 2020548995 A JP2020548995 A JP 2020548995A JP 2020548995 A JP2020548995 A JP 2020548995A JP 2021518344 A5 JP2021518344 A5 JP 2021518344A5
- Authority
- JP
- Japan
- Prior art keywords
- groups
- alkyl
- cancer
- cycloalkyl
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862644189P | 2018-03-16 | 2018-03-16 | |
| US62/644,189 | 2018-03-16 | ||
| PCT/US2019/022727 WO2019178590A1 (en) | 2018-03-16 | 2019-03-18 | Heterocyclic inhibitors of atr kinase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021518344A JP2021518344A (ja) | 2021-08-02 |
| JP2021518344A5 true JP2021518344A5 (https=) | 2022-03-22 |
| JP7341156B2 JP7341156B2 (ja) | 2023-09-08 |
Family
ID=67904811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548995A Active JP7341156B2 (ja) | 2018-03-16 | 2019-03-18 | Ａｔｒキナーゼの複素環式阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10894052B2 (https=) |
| EP (1) | EP3765008B1 (https=) |
| JP (1) | JP7341156B2 (https=) |
| CN (1) | CN112218631B (https=) |
| WO (1) | WO2019178590A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018218197A2 (en) | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| WO2019014618A1 (en) | 2017-07-13 | 2019-01-17 | Board Of Regents, University Of Texas System | HETEROCYCLIC INHIBITORS OF KINASE ATR |
| JP7290627B2 (ja) | 2017-08-17 | 2023-06-13 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| JP7341156B2 (ja) | 2018-03-16 | 2023-09-08 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| WO2022094218A1 (en) * | 2020-10-29 | 2022-05-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Process for the preparation of heteroaryl-substituted sulfur(vi) compounds |
| AU2022271549A1 (en) * | 2021-05-12 | 2023-11-16 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Sulfoximine-containing atr inhibitor compound |
| EP4342470A4 (en) * | 2021-05-18 | 2025-04-30 | Onconic Therapeutics Inc. | THERAPEUTIC AGENT FOR PARP INHIBITOR-RESISTANT CANCER |
| WO2023131234A1 (en) * | 2022-01-06 | 2023-07-13 | Shanghai Antengene Corporation Limited | Crystalline forms of an atr inhibitor |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1979325A1 (en) | 2006-01-11 | 2008-10-15 | AstraZeneca AB | Morpholino pyrimidine derivatives and their use in therapy |
| AU2007287428B2 (en) | 2006-08-24 | 2011-08-11 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| EP2064203A1 (en) | 2006-09-14 | 2009-06-03 | AstraZeneca AB | 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| EP2146981A1 (en) | 2007-04-12 | 2010-01-27 | F. Hoffmann-Roche AG | Pharmaceutical compounds |
| US20080292588A1 (en) * | 2007-05-17 | 2008-11-27 | Anadys Pharmaceuticals, Inc. | 1-methyl-benzo[1,2,4]thiadiazine 1-oxide derivatives |
| AU2008273889B2 (en) | 2007-07-09 | 2012-03-08 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| CN101809002B (zh) | 2007-07-09 | 2013-03-27 | 阿斯利康(瑞典)有限公司 | 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物 |
| BRPI0814503A2 (pt) * | 2007-07-09 | 2017-05-16 | Astrazeneca Ab | composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica |
| EP2264026A4 (en) | 2008-03-06 | 2012-03-28 | Msd Kk | ALKYLAMINOPYRIDINDERIVATE |
| US20110201599A1 (en) | 2008-07-03 | 2011-08-18 | Exelixis, Inc. | CDK Modulators |
| US20110053923A1 (en) | 2008-12-22 | 2011-03-03 | Astrazeneca | Chemical compounds 610 |
| WO2010120996A1 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| JP2013032290A (ja) | 2009-11-20 | 2013-02-14 | Dainippon Sumitomo Pharma Co Ltd | 新規縮合ピリミジン誘導体 |
| WO2011106276A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
| WO2011103715A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
| EP2542536B1 (en) | 2010-03-04 | 2015-01-21 | Cellzome Limited | Morpholino substituted urea derivatives as mtor inhibitors |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| WO2012147890A1 (ja) | 2011-04-27 | 2012-11-01 | 持田製薬株式会社 | 新規アゾール誘導体 |
| SI2941432T1 (en) | 2012-12-07 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| PT3077397T (pt) | 2013-12-06 | 2020-01-22 | Vertex Pharma | Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo |
| EP3083618B1 (en) * | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| MX373102B (es) | 2014-06-05 | 2020-04-17 | Vertex Pharma | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo. |
| TWI656121B (zh) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| KR102569226B1 (ko) | 2014-10-13 | 2023-08-22 | 아트린 파마슈티컬스 엘엘씨 | 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제 |
| CA3011189C (en) * | 2016-01-14 | 2024-02-20 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
| CA3026149A1 (en) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| WO2018218197A2 (en) | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| WO2019014618A1 (en) | 2017-07-13 | 2019-01-17 | Board Of Regents, University Of Texas System | HETEROCYCLIC INHIBITORS OF KINASE ATR |
| JP7290627B2 (ja) | 2017-08-17 | 2023-06-13 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| JP7341156B2 (ja) | 2018-03-16 | 2023-09-08 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
-
2019
- 2019-03-18 JP JP2020548995A patent/JP7341156B2/ja active Active
- 2019-03-18 US US16/356,450 patent/US10894052B2/en active Active
- 2019-03-18 CN CN201980019299.6A patent/CN112218631B/zh active Active
- 2019-03-18 WO PCT/US2019/022727 patent/WO2019178590A1/en not_active Ceased
- 2019-03-18 EP EP19767169.6A patent/EP3765008B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518344A5 (https=) | ||
| JP2020531447A5 (https=) | ||
| JP7696443B2 (ja) | Ｅｇｆｒ変異を有するがんを処置するためのアミノ置換ヘテロ環類 | |
| ES2761824T3 (es) | Compuestos de carboximidamida de benzimidazol y imidazopiridina que tienen actividad como inhibidores de indoleamina 2,3-dioxigenasa | |
| ES2539257T3 (es) | Imidazo[1,2-b]piridazinas sustituidas | |
| KR102534028B1 (ko) | 트리아졸로피리미딘 화합물 및 그의 용도 | |
| ES2392489T3 (es) | Dicarbazoles y procedimientos de uso | |
| US8003662B2 (en) | Heterobicyclic thiophene compounds and methods of use | |
| ES2558780T3 (es) | Imidazopiridazinas como inhibidores de la cinasa Akt | |
| CN115003677A (zh) | 对kras g12d突变具有抑制活性的化合物 | |
| WO2016203404A1 (en) | Compounds and compositions for inhibiting the activity of shp2 | |
| JP2022510501A (ja) | 化合物、医薬組成物、ならびに化合物の調製方法及びａｔｒキナーゼ阻害剤としてのその使用方法 | |
| JP2022515197A (ja) | がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体 | |
| RU2014130125A (ru) | Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| JP6502332B2 (ja) | 二環式アルキン誘導体およびその使用 | |
| CN114057689A (zh) | 用于抑制shp2活性的化合物和组合物 | |
| RU2018138471A (ru) | Гетероциклические соединения в качестве ингибиторов киназы RET | |
| TW200938202A (en) | Heterocyclic compounds | |
| CN102131390A (zh) | 三唑并吡啶jak抑制剂化合物和方法 | |
| EA029269B1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| JP2014503567A5 (https=) | ||
| ES2918924T3 (es) | Inhibidores de TGF-beta | |
| RU2014130129A (ru) | Новые фосфатные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| BR112012011188A2 (pt) | ''composto,composição farmacêutica e uso de um composto" | |
| US11529350B2 (en) | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |